CRISPR Therapeutics AG $CRSP Shares Acquired by Strs Ohio

Strs Ohio lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 335.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,523 shares of the company’s stock after purchasing an additional 18,123 shares during the quarter. Strs Ohio’s holdings in CRISPR Therapeutics were worth $1,525,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. Atlantic Union Bankshares Corp acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $33,000. Thompson Investment Management Inc. purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $33,000. Strategic Wealth Investment Group LLC acquired a new stake in CRISPR Therapeutics during the second quarter worth about $36,000. Bogart Wealth LLC raised its stake in CRISPR Therapeutics by 333.3% during the third quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock worth $42,000 after purchasing an additional 500 shares during the period. Finally, IFP Advisors Inc raised its position in shares of CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after buying an additional 181 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wedbush reduced their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. Wells Fargo & Company set a $75.00 target price on CRISPR Therapeutics in a report on Monday, October 13th. Royal Bank Of Canada raised their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Finally, Robert W. Baird lowered their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Twelve investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average target price of $68.15.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the transaction, the chief executive officer owned 134,201 shares in the company, valued at $8,082,926.23. This trade represents a 30.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $54.26 on Wednesday. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The firm has a market capitalization of $5.17 billion, a P/E ratio of -9.71 and a beta of 1.70. The company’s fifty day moving average price is $54.94 and its 200 day moving average price is $58.35.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.